Follow BWX Technologies to never miss an important update.
On November 3, the company reached an agreement with Wells Fargo and other lenders to extend its $1.25 billion revolving credit facility by one year. This gives the company until late 2031 to use and repay this line of credit, which acts like a large corporate credit card for its daily operations. The new terms also allow for lower interest rates if the company’s credit rating improves. For a business that builds long-term projects like nuclear reactors, having more time and potentially lower borrowing costs provides extra flexibility to manage its cash while it works through its large order backlog.
Source: 8-K filing
After BWX Technologies reported its November results, we updated our fair value and cut our quality score to 3.9. We moved our rating to Buy and added the divestiture of the medical isotope business to what we track. We have also started tracking demand for microreactor fuel and nuclear materials alongside our projections for small modular reactors. We raised our expectations for how much cash the company can generate and for how fast its commercial sales will grow.
The company reported profit of $1.26 per share, beating the $1.18 analysts expected. While revenue of $953 million was slightly below targets, the business is becoming more efficient at turning those sales into cash. The company now expects to earn between $4.72 and $4.77 per share for the full year, a tighter and slightly higher range than before.
Two new projects highlight the company's move into small, portable nuclear reactors. Its technology was selected for a U.S. Army program in Kentucky and a transportable power plant project in Canada. These wins help prove the company can grow beyond its core business of building reactors for Navy submarines and aircraft carriers. Management also shared an early look at 2027, expecting profit growth to reach double digits as these new energy and defense projects scale up.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company is expected to report its latest quarterly results later today. Analysts are looking for earnings of about $1.18 per share on revenue of roughly $970 million. Beyond the headline numbers, the focus remains on how well the company is turning its large backlog of naval contracts into actual sales. We are also looking for updates on its medical isotope business, which is the key to expanding its profit margins beyond its steady government work.
BWX Technologies will produce TRISO fuel, a specialized nuclear fuel designed to be more stable and heat-resistant than traditional options, for Antares Nuclear. The agreement starts with a one-ton allocation of uranium and allows for more production as Antares builds out its reactor program.
While the company is best known for powering Navy ships, this deal shows it is successfully winning work in the emerging market for small, advanced reactors. It is a small start, but it helps prove that the company's expertise in nuclear manufacturing can translate into commercial sales beyond its steady government contracts.
Source: Business Wire
Management has beaten profit expectations for eight straight quarters, showing they set conservative targets they can reliably clear as naval and commercial nuclear projects ramp up.
| Expectation | |
|---|---|
| EPS | $1.33 |
| Revenue | $1.08B |
Follow BWX Technologies to get the latest and most important updates.
Follow BWXT